Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer

Oncology Reports

Volumn 19, Issue 3, 2008, Pages 651-656

  Kammori, Makoto ^a,d   Kurabayahi, Rie ^b,c   Kashio, Mitsuhiko ^c,d   Sakamoto, Akiko ^d   Yoshimoto, Masataka ^e   Amano, Sadao ^d   Kaminishi, Michio ^b   Yamada, Tetsu ^a   Takubo, Kaiyo ^c  

^a Kanaji Thyroid Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Breast cancer; Estrogen receptor; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 40249084689     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.3.651     Document Type: Article

References (19)